Abstract
Background: While cigarette smoking has declined among the U.S. general population, sale and use of non-cigarette alternative tobacco products (ATP; e.g., e-cigarettes, cigars) and dual use of cigarettes/ATPs are rising. Little is known about ATP use patterns in cancer survivors enrolled in clinical trials. We investigated prevalence of tobacco product use, and factors associated with past 30-day use, among patients with cancer in national trials. Methods: Cancer survivors (N = 756) enrolled in 9 ECOG-ACRIN clinical trials (2017–2021) completed a modified Cancer Patient Tobacco Use Questionnaire (C-TUQ) which assessed baseline cigarette and ATP use since cancer diagnosis and in the past 30 days. Results: Patients were on average 59 years old, 70% male, and the mean time since cancer diagnosis was 26 months. Since diagnosis, cigarettes (21%) were the most common tobacco product used, followed by smokeless tobacco use (5%), cigars (4%), and e-cigarettes (2%). In the past 30 days, 12% of patients reported smoking cigarettes, 4% cigars, 4% using smokeless tobacco, and 2% e-cigarettes. Since cancer diagnosis, 5.5% of the sample reported multiple tobacco product use, and 3.0% reported multiple product use in the past 30 days. Males (vs. females; OR 4.33; P = 0 < 0.01) and individuals not living with another person who smokes (vs. living with; OR, 8.07; P = 0 < 0.01) were more likely to use ATPs only versus cigarettes only in the past 30 days. Conclusions: Among patients with cancer, cigarettes were the most prevalent tobacco product reported. Impact: Regardless, ATPs and multiple tobacco product use should be routinely assessed in cancer care settings.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1552-1557 |
| Number of pages | 6 |
| Journal | Cancer Epidemiology Biomarkers and Prevention |
| Volume | 32 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 1 2023 |
Funding
This study was conducted by the ECOG-ACRIN Cancer Research Group (Peter J. O’Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and supported by the NCI of the NIH under the following parent award numbers: U10CA180794, UG1CA189828, U10CA180820, UG1CA232760, UG1CA233180, UG1CA233198, UG1CA233247, UG1CA233270, UG1CA233277, UG1CA233290, UG1CA233320, UG1CA239758. This project was funded by two supplements to the ECOG-ACRIN parent grants. A supplement to the ECOG-ACRIN NCORP Research Base grant (L. Wagner, P.J. O’Dwyer, M.D. Schnall) and a supplement to the NCTN grant (O’Dwyer, Schnall). J.W. Lee reports grants from NCI during the conduct of the study. I.F. Gareen reports grants from NCI during the conduct of the study. R.C. Carlos reports grants from NIH/ECOG-ACRIN during the conduct of the study; other support from JACR outside the submitted work. S. Kumar reports Research funding for clinical trials to the institution: AbbVie, Amgen, Allogene, Bristol-Myers Squibb, Carsgen, GSK, Janssen, Roche-Genentech, Takeda, Regeneron; Consulting/Advisory Board participation: (with no personal payments) AbbVie, Bristol-Myers Squibb, Janssen, Roche-Genentech, Takeda, Pfizer, Loxo Oncology, K36, Sanofi, ArcellX, Beigene, and (with personal payment) Oncopeptides, Antengene. I.A. Mayer reports other support from AstraZeneca outside the submitted work. N.F. Saba reports Advisory role for: GSK, Merck, CUE, Exelixis, Eisai, Bristol-Myers Squibb, Aveo, Inovio, Coherus. J.W. Neal reports personal fees from see below outside the submitted work; and Research Funding from Genentech/Roche, Merck, Novartis, Boehringer Ingelheim, Exelixis, Nektar, Takeda, Adaptimmune, GlaxoSmithKline, Janssen, AbbVie, Novocure; Consulting or advisory role at AstraZeneca, Genentech/Roche, Exelixis, Takeda, Lilly, Amgen, Iovance Biotherapeutics, Blueprint Medicines, Regeneron, Natera, Sanofi/ Regeneron, D2G Oncology, Surface Oncology, Turning Point Therapeutics, Mirati Therapeutics, Gilead Sciences, AbbVie, Summit Therapeutics, Novartis, Novocure. M.B. Atkins reports personal fees from Bristol-Myers Squibb, Eisai, Aveo, Pfizer, Fathom, Valohealth, Scholar Rock, Surface, Takeda, Roche, SAB Bio, Exelixis, Asher Bio, AstraZeneca, SeaGen, Sanofi, Pliant RX, GSK, Atreca, SIMCHA; and personal fees from Novartis during the conduct of the study; grants and personal fees from Merck, Pyxis Oncology, Werewolf; and personal fees from Elpis outside the submitted work. F.S. Hodi reports other support from CTEP/NCI during the conduct of the study; grants and personal fees from Bristol-Myers Squibb; personal fees from Merck, Novartis, Surface, Compass Therapeutics, Bicara, Pieris Pharmaceutical, Checkpoint therapeutics, Genentech, Bioentre, Gossamer, Iovance, Catalym, Immunocore, Kairos, Rheos, Zumutor, Corner Therapeutics, Curis; and personal fees from Astra-Zeneca outside the submitted work; in addition, F.S. Hodi has a patent for Methods
ASJC Scopus subject areas
- General Medicine
